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ABSTRACT
Objectives: Absence of a functional interferon-k 4 (IFN-k4) gene (IFNL4) predicts spontaneous reso-
lution of acute hepatitis C virus (HCV) infections in regions with a predominance of genotype 1,
whereas variants of the inosine triphosphate pyrophosphatase (ITPase) gene (ITPA) entailing reduced
activity associate with increased sustained virologic response rates following some therapeutic regi-
mens. This study aimed at investigating the impact of IFNL4 on acute HCV genotype 2 or 3 infections,
and whether ITPase activity influenced outcome.
Materials and Methods: Two hundred and seven people who injected drugs (PWID) with docu-
mented anti-HCV seroconversion, and 57 PWID with reinfection with HCV were analyzed regarding
IFNL4 (rs368234815 and rs12979860) and ITPA (rs1127354 and rs7270101), and longitudinally followed
regarding HCV RNA.
Results: The spontaneous clearance of HCV infection in anti-HCV seronegative PWID was enhanced
when IFN-k4 was absent (44% vs. 20% for IFNL4 TT/TTrs1368234815 and DGrs1368234815 respectively,
p< .001; OR 3.2) across genotypes 1-3. The proportion lacking IFN-k4 was further increased following
resolution of repeated re-exposure to HCV (74% among re-infected participants who had cleared at
least two documented HCV infections). ITPA genetic variants did not independently impact on the out-
come, but among males lacking IFN-k4, reduced ITPase activity markedly augmented the likelihood of
resolution (65% vs. 29% for <100% and 100% ITPase activity, p¼ .006).
Conclusions: Absence of IFN-k4 entails an enhanced likelihood of spontaneous resolution both follow-
ing primary acute infection and repeated re-exposure to HCV across genotypes 1-3. Among men lack-
ing IFN-k4, reduced ITPase activity improved outcome.
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Approximately 15-40% of exposed individuals spontaneously
resolve acute hepatitis C virus (HCV) infection [1].
Homozygous carriage of the C allele in rs12979860 on
chromosome 19, in the proximity of the interleukin 28B gene
(IL28B) also known as interferon-k 3 (IFNL3), increases the
likelihood of clearance, especially in geographical regions
with a predominance of HCV genotype 1 [2,3]. Recently,
however, this polymorphism was found to be located in
intron 1 in a previously overlooked gene encoding inter-
feron-k4 (IFNL4), with the C allele in rs12979860 being in
strong linkage disequilibrium (LD) with an insertion/deletion
polymorphism, rs368234815, in IFNL4 exon 1. Humans are
polymorphic for the dinucleotide TT/DG allele in
rs368234815 [4], with the TT allele resulting in a disruptive
frameshift in the coding region of IFNL4, subsequently entail-
ing pseudogenization and abrogated IFN-k4 production. In
contrast, the ancestral wild-type allele DGrs368234815, which is
present in non-human primates, allows for production of
IFN-k4.
Two SNPs in the inosine triphosphate pyrophosphatase
(ITPase) gene (ITPA), resulting in a missense variant in exon 2
(rs1127354, P32T) and a splice-altering single nucleotide poly-
morphism (SNP) in intron 2 (rs7270101, IVS2) on chromosome
20, have been demonstrated in a genome-wide association
study (GWAS) to protect against ribavirin-induced hemolytic
anemia during therapy with IFN-a and ribavirin for HCV
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infection [5,6], with minor allele carriage resulting in reduced
ITPase activity [7]. Reduced ITPase activity, present in
approximately one third of HCV infected patients, was signifi-
cantly associated with increased treatment efficacy mediated
by reduced relapse risk following interferon-based therapy
for HCV genotype 2/3 [8]. Furthermore, among HCV geno-
type 1 or 3 infected patients with baseline NS5A resistance-
associated substitutions (RASs), reduced ITPase activity
improved outcome following some direct acting anti-viral
(DAA) regimens [9] secondary to a ribavirin-like reduced
relapse risk.
The onset of hepatitis C virus (HCV) infection is often chal-
lenging to determine due to the frequent absence of symp-
toms [10]. However, frequent serological and molecular
surveillance of high-risk populations can uniquely identify
acute HCV infections. Two recent Swedish studies investi-
gated HCV incidence and spontaneous clearance rates of
incident HCV in people who inject drugs (PWID). In the study
from Southern Sweden (Malm€o), antibodies against HCV
were detected at study entry in 60%, and the incidence of
new HCV infections was 31/100 person years, with spontan-
eous clearance seen in 32% [11]. In the study from the
Stockholm, baseline anti-HCV antibodies were detected in
77% and ongoing infection in 57%. The incidence of HCV
infection in HCV seronegative patients was 26/100 person
years, and 19/100 person years in participants with evidence
of previous exposure (detectable anti-HCV antibodies but
undetectable HCV-RNA). Spontaneous clearance was seen in
20% of seronegative patients and in 44% of those with docu-
mented previous exposure [12].
As most studies on acute HCV infection have been con-
ducted in areas with a predominance of HCV genotype 1,
this study aimed at investigating spontaneous HCV clearance
and host genetic variants in IFNL4 and ITPA in a geographic
region with prevalence of HCV genotypes 1, 2 and 3.
Materials and methods
Study population
Patients were recruited from two different needle exchange
programs (NEPs), i.e., in Malm€o and Stockholm, Sweden.
Upon entry to the NEP, the initial baseline serum sample was
analyzed for serologies for human immunodeficiency virus
(HIV), hepatitis A virus (HAV), hepatitis B surface antigen
(HBsAg), hepatitis B core antibody (anti-HBc), and anti-HCV
serologies. Subsequently, the participants lacking antibodies
against respective virus at enrollment were requested to
undergo prospective serologically testing for anti-HIV, HBsAg
and anti-HCV at three to six months’ intervals. In Stockholm,
HCV RNA was quantified among anti-HCV positive partici-
pants at enrollment, and those lacking detectable HCV RNA
were included in the present study. Participants from both
cohorts lacking exposure to HBV at enrollment were offered
vaccination. Samples from Malm€o cohort were analyzed first,
and to validate the findings from this first evaluation, sam-
ples from the Stockholm cohort were subsequently analyzed.
As this latter cohort was continuously monitored by means
of HCV RNA analysis, the Stockholm material allowed for the
additional analysis of patients with reinfection after initially
spontaneously clearing an HCV infection.
In the present study, participants from both cohorts who
were anti-HCV negative at enrollment, as well as anti-HCV
positive but HCV-RNA negative at entry (indicative of past
spontaneous clearance of previous HCV exposure) from the
Stockholm cohort, were eligible for inclusion. One hundred
fifty of 186 anti-HCV seroconverters from the Malm€o NEP
participants had complete series of pre-baseline, baseline
and 1 year follow up HCV-RNA testing, and samples from
one hundred thirty nine of these 150 individuals were avail-
able for host genetic testing, constituting the Malm€o study
cohort (Figure 1).
Among the Stockholm NEP participants, 114 anti-HCV
negative participants at enrollment who later seroconverted
against HCV during the longitudinal study indicating acute
HCV infection were identified. Of these 114 patients, 95 sam-
ples were available for analyses, and 68 of these patients
had had an HCV-RNA test performed >5months after con-
version and were thus included in the study. Ninety-three
patients, who had anti-HCV antibodies but HCV RNA
undetectable at enrollment (i.e., had resolved at least one
prior exposure to HCV), subsequently became re-infected,
and of these patients, 57 were available for analysis and had
a follow up HCV RNA test >5months past reinfection (Figure
1). Five patients from the Stockholm cohort had HIV infection
and five had ongoing HBV infection at enrollment.
Definition of spontaneous viral clearance
Spontaneous viral clearance was defined as the absence of
viremia in one follow-up sample drawn approximately
12months after the appearance of anti-HCV antibodies in
the Malm€o cohort, and in the Stockholm cohort as viral
clearance in a sample taken >5months after either HCV
seroconversion or HCV-RNA positivity in patients with previ-
ously cleared infections.
HCV-RNA detection and genotyping
All HCV RNA samples were analyzed by Roche COBAS
AmpliPrep/COBAS TaqMan HCV Test as described by the
manufacturer. All testing from the Malm€o cohort was per-
formed at 1/10 dilution in negative serum due to limitations
regarding sample volume, hence test sensitivity for these
samples was decreased tenfold. Viral genotyping on the first
viremic sample in the Malm€o cohort was performed by
phylogenetic analysis of 321 nucleotides of the NS5B region
[13]. HCV genotyping was not assessed in the Stockholm
cohort. Information regarding symptoms in conjunction with
sampling was not available.
IFNL4 and ITPA genotyping
Two sites were chosen in chromosome 19 (rs12979860 and
rs368234815) involved in the expression of IFNL4 and two in
chromosome 20 (rs1127354 and rs7270101) known to predict
ITPase activity. Briefly: rs1127354 CC and rs7270101 AA
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corresponds to 100% ITPase activity, CC and AC to 60%, AC
and AA to 25%, AC and AC to 10%, and AA and AA to less
than 5% respectively [7]. Polymorphisms were determined in
serum by allelic discrimination using Taq-Man SNP Assays
(Life Technologies) for rs7270101, rs1127354, rs368234815/
ss469415590 and for rs12979860 using an in-house test as
described previously [14]. As IFNL4 and ITPA are located on
chromosomes 19 and 20 respectively, and these genes are
unlinked and not in linkage disequilibrium, as chromosomes
are segregated independently during meiosis.
Statistical analyses
Chi-Square test or Fisher’s exact test was used to evaluate
differences in spontaneous resolution of infection and geno-
type distribution. One-way analysis of variance (ANOVA) fol-
lowed by Dunnett’s multiple comparison test on logarithmic
values were used for multiple comparisons of age in the
IFNL4 genotype and predicted ITPase activity subgroups.
Welch’s T-test on logarithmic values was used when compar-
ing age between two groups of patients. Statistics was done
in Prism (Version 6.0c, GraphPad Software, La Jolla, CA) or
SPSS (Version 20.0.0, IBM Corp, Armonk, NY, USA) software.
All reported P values are two-sided, and p values <.05 were
considered significant.
Ethical considerations
The original study was approved by the Regional Research
Ethics Committee in Lund (no 195/2005) which allowed for
consent for the retro- and prospective studies at the NEP to
be obtained by an opt-out arrangement, through advertise-
ments in two daily local papers and multiple posters at the
NEP itself. The study in Stockholm was approved by the




The baseline characteristics of the participants are summar-
ized in Table 1. The gender distribution was skewed towards
fewer women, similar across HCV genotypes. Interestingly, in
the Stockholm cohort re-infected patients had a higher clear-
ance rate of 67% as compared to 26% among the partici-
pants who were anti-HCV negative at enrollment. Aside from
this, the clearance rates were similar across genotypes and
cohorts. Among anti-HCV negative patients at enrollment
developing an acute HCV infection during the study, 45%
lacked IFN-k4 (IFNL4 TTrs368234815 homozygotic), whereas the
corresponding proportion among re-infected patients
was 67%.
IFNL4 and ITPase activity and spontaneous resolution
of HCV infection
In anti-HCV seronegative patients at enrollment, 41 of 94
(44%) of participants lacked IFN-k4 (IFNL4 TTrs368234815 homo-
zygotes) vs. 22/113 (20%) of those with at least one func-
tional gene (IFNL4 DGrs368234815 carriers) spontaneously
cleared their infection (p< .001, Odds ratio (OR) 3.2, 95%
confidence interval (CI) 1.7 to 6.0)) [Figure 2(A)].
The association between absence of IFN-k4 and greater
likelihood of spontaneous resolution of HCV infection
remained significant both for HCV genotype 1 infected per-
sons (38% vs. 12% for IFNL4 TTrs1368234815 homozygotes and
DGrs368234815 carriers respectively, p¼ .02; OR 4.4 (95% CI 1.2
to 16.0)), and for HCV genotype 2 or 3 when analyzed
together (39% vs. 13% for IFNL4 TTrs1368234815 homozygotes
and DGrs368234815 carriers respectively, p¼ .03; OR 4.4 (95% CI
1.1 to 13.8)) [Figure 2(A)]. A similar, non-significant trend was
seen when this latter group was further subdivided by geno-
types 2 and 3; 3/6 (50%) vs. 0/5 (0%) for genotype 2 (p¼ .18,
OR 1 (95% CI 0.8; 1)), and 8/22 (36%) vs. 4/26 for genotype
3 (15.0%) (p¼ .11, OR 3.1 (95% CI 0.8–10.5)).
Figure 1. Flowchart of patients in the study. NEP (needle exchange program), PWID (person who inject drugs), anti-HCV seronegative (anti-HCV antibody assay
below the cut-off level of detection at inclusion), and anti-HCV seropositive (anti-HCV antibody assay above the cut-off level of detection at inclusion).
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Re-infected subjects had an overall higher clearance rate
of 67%, and among these participants there was a similar,
non-significant trend towards higher clearance rates among
individuals lacking IFN-k4 (74% vs. 53% for IFNL4 TTrs368234815
homozygotes and DGrs1368234815 carriers respectively, p¼ .1,
OR 2.5 (95% CI 0.7–7.3)). Moreover, a significant increase in
proportion of patients lacking IFN-k4 (IFNL4 TTrs368234815
homozygotes) was observed when comparing the following
groups: (i) anti-HCV seronegative patients at enrollment with-
out spontaneous clearance after exposure to HCV during the
follow-up study period, (ii) re-infected patients unable to
clear re-infection, (iii) anti-HCV seronegative patients at
enrollment clearing their first documented HCV infection,
and (iv) Re-infected patients who had cleared at least two
documented HCV infections [Figure 2(Bp< .001, Chi-2 test].
In contrast to IFNL4 genetic variants, spontaneous clear-
ance of HCV was not significantly associated with predicted
ITPase activity when analyzed independently. However, when
restricting the analysis to subjects lacking IFN-k4 (IFNL4
TTrs368234815 homozygotic), men with reduced predicted
Table 1. Baseline characteristics for different cohorts and accordning to hepatitis C virus genotype.
Malm€o NEP Cohort Stockholm NEP Cohort
HCV-IgG
seroconversion with























29.5 ± 8.0 28.7 ± 7.6 31.9 ± 10.4 29.7 ± 7.9 29.8 ± 8.3 40.1 ± 9.9
Female gender,
n (%)
28 (20%) 13 (21%) 2 (18%) 10 (21%) 23 (34%) 17 (30.0%)
pITPase activity
<100%, n (%)
46 (33%) 21 (34%) 4 (36%) 15 (31%) 25 (37%) 15 (26%)
IFNL4 RS368234815
TTTT, n (%)
60 (43%) 21 (34%) 6 (55%) 23 (48%) 34 (50%) 38 (67%)
Spontaneous
Clearence, n (%)
45 (32%) 13 (21%) 3 (27%) 12 (25%) 18 (26%) 38 (67%)
For categorical variables numbers (n) and percent (%) is displayed and for continues variables mean with standard deviation (SD). pITPase, predicted inosine tri-
phosphate pyrophosphatase activity, IFNL4, interferon k 4, FU follow up, NEP, needle exchange program.
Figure 2. (A) Percentage of spontaneous clearance of HCV infection in relation to absence of IFN-k4 (IFNL4rs368234815 TT/TT) or presence of IFN-k4 (IFNL4rs368234815
DG) for all HCV genotypes (gt), genotype 1, genotype 2/3 together and Re-infected PWID participants; statistics using Fischer’s exact test. (B) Proportion of patients
with absence of IFN-k4 (IFNL4rs368234815 TT/TT) or presence of IFN-k4 (IFNL4rs368234815 DG) in four different groups; anti-HCV seronegative participants at enrollment
without spontaneous clearance (SC-), Re-infected participants unable to clear their re-infection (SCþ SC-), anti-HCV seronegative participants at enrollment clearing
their first documented HCV infection (SCþ), and Re-infected participants who had cleared at least two documented HCV infections (SCþ SCþ), statistics using
Chi2 test.
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ITPase activity (defined as <100%) were significantly more
likely to spontaneously resolve the HCV infection as com-
pared to those with normal ITPase enzymatic activity (Figure
3; 65% vs. 30% for ITPase <100% and 100% respectively,
p¼ .006). This difference was not observed among men able
to produce IFN-k4 (IFNL4 DGrs368234815 carriers) (Figure 3), nor
among female patients, although it is important to note that
only 51 women were enrolled in the PWID cohorts, making
female-gender related subgroup analyses challenging.
Multivariate analysis and spontaneous resolution of
HCV-infection
To further analyze the impact host genetic variants on spon-
taneous clearance, a multivariate analysis was performed
including gender, age at seroconversion for HCV, ITPase
activity (<100% or 100%), HCV genotype, and absence or
presence of IFN-k4 (IFNL4 TTrs1368234815 homozygote or
DGrs368234815 carriage). In this analysis only absence of IFN-k4
(IFNL4 TTrs368234815 homozygosity) (p¼ .002, adjusted OR 4.7
(95% CI 1.7–12.5)) and female gender (p¼ .007, adjusted OR
4.1 (95% CI 1.5–11.8)) were significantly associated with
spontaneous clearance of acute incident HCV infection.
A separate multivariate analysis was performed for the
whole study population, including previous anti-HCV status:
(1) subjects seroconverting against HCV and (2) re-infected
patients, but not including HCV genotype as this was only
analyzed in the Malm€o cohort. In this analysis, only absence
of IFN-k4 (IFNL4 TTrs368234815 homozygosity) (p¼ .0002,
adjusted OR 2.9 (95% CI 1.7–5.0)) and PWID cohort
(p¼ .0002, adjusted OR 4.0 (95% CI 1.9–8.3)) were signifi-
cantly associated with spontaneous clearance of acute inci-
dent HCV infection.
Discussion
The main findings of this study were that absence of IFN-k4
is associated with enhanced spontaneous clearance of HCV
infection across genotypes 1-3, and that among men lacking
IFN-k4, reduced ITPase activity augmented the likelihood of
spontaneous resolution.
IFNL4 polymorphisms have been extensively evaluated in
HCV infection, especially as prognostic markers of respon-
siveness to interferon and ribavirin combination treatment,
but also in the context of resolution of acute HCV infection
[2,15]. Most prior studies have been conducted in geograph-
ical regions with a predominance of HCV genotype 1, but a
recent meta-analysis confirmed the importance of these poly-
morphisms in interferon-based treatment for genotype 2 or
3 infection [16]. Studies on the impact of IFNL4 polymor-
phisms in acute infection with HCV genotype 2 or 3 are rare,
which may be explained by difficulties in identifying subjects
early during infection to allow for detection of HCV RNA and
genotyping. The association of absence of IFN-k4
(CCrs12979860 carriage) and spontaneous clearance among
non-1 HCV genotypes has previously been reported in a
study where the majority of enrolled patients had genotype
2 or 3 infection [17], and also in a cohort of patients with
thalassemia and a predominance of acute HCV genotype 3
infection [17,18]. In the present study, PWID were longitudin-
ally monitored at intervals of approximately 3months leading
to high precision of estimating the onset of HCV infection
and also to a high HCV-RNA detection rate allowing for HCV
genotyping in 121 of 139 participants from the Malm€o
cohort. The association between inability to produce IFN-k4
(TTrs368234815 homozygosity) and increased likelihood of spon-
taneous resolution following incident exposure thus could be
confirmed for HCV genotypes 1 and 2/3.
The impact of IFNL4 on spontaneous resolution in subjects
who previously had cured at least one documented HCV
infection was also analyzed, and an accumulation of partici-
pants lacking IFN-k4 (TTrs368234815 homozygosity) was
observed in the re-infected group, with the proportion lack-
ing IFN-k4 increasing among subjects that were able to also
clear the reinfection. The clearance rate following reinfection
among PWID lacking IFN-k4 was relatively high at 74% as
compared with 53% if one or two functional IFNL4 genes
were present. These observations are in line with a well-char-
acterized, albeit small multicenter study, where a borderline
significant association with higher clearance among patients
without IFN-k4 (CCrs12979860) was reported among 28 HCV re-
infected subjects [19]. The difference in the present study
also demonstrated borderline significance, but a clear accu-
mulation of subjects lacking IFN-k4 in spontaneous clearers
and in individuals resolving at least two documented HCV
infections was noted. The combined results of the above-
mentioned [19] and the present study, provide increasing
Figure 3. Percentage of spontaneous clearance of HCV infection for male PWID
participants in relation to absence of IFN-k4 (IFNL4rs368234815 TT/TT) or presence
of IFN-k4 (IFNL4rs368234815 DG) and ITPase activity (<100% or 100%); statistics
using Fischer’s exact test.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 5
evidence of absence of IFN-k4 entailing enhanced likelihood
of spontaneous HCV clearance both following primary acute
infection and repeated re-exposure to HCV. This may have
implications regarding the need for follow-up after HCV ther-
apy among PWID, where individuals capable of producing
IFN-k4 likely require more stringent monitoring as they are
more prone to become reinfected following renewed
HCV exposure.
Prior to initiating the present study, we hypothesized that
among patients lacking IFN-k4, reduced ITPase activity might
be additionally beneficial based on prior studies [8,9].
Indeed, a highly significant association to this effect was
noted among male patients lacking IFN-k4 (TTrs368234815
homozygous), where reduced ITPase activity improved the
likelihood to spontaneously resolve to 65%, as compared to
30% in those with full enzymatic activity. Interestingly, the
abovementioned association was absent among female par-
ticipants, which might be secondary to the small number of
female participants in the present study, but might addition-
ally by explained by well-documented gender differences in
immune responses observed in numerous vaccine trials [20],
as well as outcome following several other viral infections, as
recently demonstrated by the higher mortality noted among
male COVID-19 patients [21].
ITPase is an enzyme that metabolizes non-canonical tri-
phosphate nucleotides (e.g., XTP and ITP, Figure 4), which
otherwise might be incorporated in host or viral genomes.
Additionally, ribavirin triphosphate (RTP) is dephosphorylated
by ITPase in vitro to ribavirin monophosphate (RMP) at a
comparable rate to ITP [9]. Inosine containing single-stranded
RNA is highly immunogenic and could theoretically cause a
better immune response [22,23]. In line with this notion is
the previously reported ability of ribavirin, which inhibits the
enzyme inosine-50-monophosphate dehydrogenase (IMPDH)
which converts IMP to XMP, to act as an immunomodulatory
compound affecting the Th1/Th2 balance [24,25].
There are certain limitations in the present study. Patients
were defined as spontaneous clearers based on undetectable
HCV RNA in one sample. The samples were obtained
approximately one year after seroconversion in the Malm€o
cohort and >5months past reinfection, and thus the two
cohorts had slightly differing sampling timepoints. Also, dur-
ing the first year we have earlier reported very divergent pat-
terns of viremia with some patients still having very low-
level HCV viremia at their one-year visit [26]. The sera also
were diluted 1/10 prior to HCV RNA analysis in the Malm€o
cohort because of limited sample volume availability, which
potentially may have led to a slightly overestimated clear-
ance rate. Additionally, genotyping was performed only once
in the Malm€o cohort and was not assessed in the Stockholm
cohort. As the incidence of re-infection among these PWID
was 31/100 person-years with a potential risk of misclassify-
ing a spontaneous clearer with re-infection with a new geno-
type as being a chronically infected person. In 18 individuals,
the HCV genotype could not be determined, and 9 of these
participants never had detectable HCV-RNA in spite of docu-
mented seroconversion, presumably due to a missed short
viremia peak occurring between available samples.
In conclusion, the present study demonstrated that IFNL4
genetic variants resulting in inability to produce IFN-k4 are
linked with improved likelihood of spontaneous clearance
both following primary acute infection and repeated re-
exposure to HCV across genotypes 1–3. Additionally, among
men lacking IFN-k4, reduced ITPase activity significantly aug-
mented the likelihood of resolution.
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Figure 4. Inosine triphosphate (ITP) to guanosine monophosphate (GMP) and adenosine monophosphate (AMP) pathways.
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